0001752724-19-034863.txt : 20190513 0001752724-19-034863.hdr.sgml : 20190513 20190513130314 ACCESSION NUMBER: 0001752724-19-034863 CONFORMED SUBMISSION TYPE: N-CEN PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190228 FILED AS OF DATE: 20190513 DATE AS OF CHANGE: 20190513 EFFECTIVENESS DATE: 20190513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JPMorgan Institutional Trust CENTRAL INDEX KEY: 0001303608 IRS NUMBER: 201491791 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: N-CEN SEC ACT: 1940 Act SEC FILE NUMBER: 811-21638 FILM NUMBER: 19817693 BUSINESS ADDRESS: STREET 1: 277 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10172 BUSINESS PHONE: 800-480-4111 MAIL ADDRESS: STREET 1: 277 PARK AVENUE CITY: NEW YORK STATE: NY ZIP: 10172 0001303608 S000007336 JPMorgan Intermediate Bond Trust C000020140 JPMorgan Intermediate Bond Trust 0001303608 S000007337 JPMorgan Core Bond Trust C000020141 JPMorgan Core Bond Trust 0001303608 S000007338 JPMorgan Equity Index Trust C000020142 JPMorgan Equity Index Trust N-CEN 1 primary_doc.xml X0201 N-CEN LIVE 0001303608 XXXXXXXX 811-21638 N-1A true JPMorgan Institutional Trust 811-21638 0001303608 5493005FRK56SHN6MJ34 277 Park Avenue New York 10172 US-NY US 800-343-1113 JPMorgan Chase Bank, N.A. 383 Madison Ave New York 10179 2122706000 records relating to its functions as sub-administrator and fund accounting agent J.P. Morgan Investment Management Inc. 383 Madison Ave New York 10179 8003431113 records relating to its functions as investment adviser and administrator JPMorgan Chase Bank, N.A. 4 Chase Metrotech Center Brooklyn 11245 7182420609 records relating to its functions as custodian DST Asset Manager Solutions, Inc. 2000 Old Colony Drive Quincy 02169 6174835000 records relating to its functions as transfer agent J.P. Morgan Institutional Investments, Inc. 383 Madison Ave New York 10179 2015951958 records relating to its functions as placement agent Y N N-1A 2 N Marian U. Pardo N/A N Peter C. Marshall N/A N Raymond Kanner N/A N Dr. Robert A. Oden, Jr. N/A N Mitchell M. Merin N/A N Dr. Matthew Goldstein N/A N Mary E. Martinez N/A N Marilyn McCoy N/A N John F. Finn N/A N Frankie D. Hughes N/A N Dennis P. Harrington N/A N Stephen P. Fisher N/A N Kathleen M. Gallagher N/A N Stephen M. Ungerman 002315698 277 Park Avenue New York 10172 XXXXXX N N N N N N JPMORGAN DISTRIBUTION SERVICES, INC. 8-52700 000104234 N/A Y N PRICEWATERHOUSECOOPERS, LLP 238 5493002GVO7EO8RNNS37 N N N N N N JPMorgan Intermediate Bond Trust S000007336 5493001V1VDT1J53V683 Y 0 0 0 N/A N N Y N CITIBANK N.A. E57ODZWZ7FF32TWEFA76 N N Revenue sharing split Cash collateral reinvestment fee N/A N/A Rule 32a-4 (17 CFR 270.32a-4) Rule 10f-3 (17 CFR 270.10f-3) Rule 22d-1 (17 CFR 270.22d-1) Rule 12d1-1 (17 CFR 270.12d1-1) Y Y N N J.P. Morgan Investment Management Inc. 801-21011 000107038 549300W78QHV4XMM6K69 N DST Asset Manager Solutions, Inc. 84-00896 N/A N N N ICE Data Pricing & Reference Data, LLC 000110037 CRD N PricingDirect Inc. 549300WIC0TOJ7N7GD54 Y N JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 Y N Self - rule 17f-2 (17 CFR 270.17f-2) Credit Suisse Securities (USA) LLC 1V8Y6QCX6YMJ2OELII46 N Y Futures commission merchants and commodity clearing organizations - rule 17f-6 (17 CFR 270.17f-6) N N J.P. Morgan Investment Management Inc. 549300W78QHV4XMM6K69 Y N JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 Y Y N 0 Deutsche Bank Securities, Inc. 8-17822 000002525 9J6MBOOO7BECTDTUZW19 4379299.00000000 Citadel Securities LLC 8-53574 000116797 12UUJYTN7D3SW8KCSG25 5420898.00000000 Merrill Lynch, Pierce, Fenner & Smith, Inc. 8-07221 000007691 8NAV47T0Y26Q87Y0QP81 21703361.00000000 HSBC Securities (USA) Inc. 8-41562 000019585 CYYGQCGNHMHPSMRL3R97 1700570.00000000 Barclays Capital, Inc. 8-41342 000019714 AC28XWWI3WIBK2824319 3574854.00000000 Citigroup Global Markets Inc. 8-08177 000007059 MBNUM2BPBDO7JBLYG310 18031969.00000000 Goldman Sachs & Co. LLC 8-00129 000000361 FOR8UP27PHTHYVLBNG30 3490351.00000000 Morgan Stanley & Co., Inc. 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 6993411.00000000 Nomura Securities International, Inc. 8-15255 000004297 OXTKY6Q8X53C9ILVV871 9119517.00000000 Wells Fargo Securities LLC 8-65876 000126292 VYVVCKR63DVZZN70PB21 3090555.00000000 90784193.00000000 N 151678441.75000000 Uncommitted 100000000.00000000 N Committed 1500000000.00000000 N N N N JPMorgan Core Bond Trust S000007337 549300Q7485FUJKEMM46 Y 0 0 0 N/A N N Y N N CITIBANK N.A. E57ODZWZ7FF32TWEFA76 N N Cash collateral reinvestment fee Revenue sharing split 919692.00 162.73000000 Rule 32a-4 (17 CFR 270.32a-4) Rule 22d-1 (17 CFR 270.22d-1) Rule 12d1-1 (17 CFR 270.12d1-1) Rule 10f-3 (17 CFR 270.10f-3) Y Y N N J.P. Morgan Investment Management Inc. 801-21011 000107038 549300W78QHV4XMM6K69 N DST Asset Manager Solutions, Inc. 84-00896 N/A N N N PricingDirect Inc. 549300WIC0TOJ7N7GD54 Y ICE Data Pricing & Reference Data, LLC 000110037 CRD N N JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 Y N Self - rule 17f-2 (17 CFR 270.17f-2) Credit Suisse Securities (USA) LLC 1V8Y6QCX6YMJ2OELII46 N Y Futures commission merchants and commodity clearing organizations - rule 17f-6 (17 CFR 270.17f-6) N N J.P. Morgan Investment Management Inc. 549300W78QHV4XMM6K69 Y N JPMorgan Chase Bank, N.A. 7H6GLXDRUGQFU57RNE97 Y Y N 0 Credit Suisse Securities (USA) LLC 8-00422 000000816 1V8Y6QCX6YMJ2OELII46 46666410.00000000 Merrill Lynch, Pierce, Fenner & Smith, Inc. 8-07221 000007691 8NAV47T0Y26Q87Y0QP81 56680458.00000000 Citigroup Global Markets Inc. 8-08177 000007059 MBNUM2BPBDO7JBLYG310 111395289.00000000 HSBC Securities (USA) Inc. 8-41562 000019585 CYYGQCGNHMHPSMRL3R97 54184371.00000000 Goldman Sachs & Co. LLC 8-00129 000000361 FOR8UP27PHTHYVLBNG30 92409079.00000000 Industrial and Commercial Bank of China Financial Services LLC 8-66471 000131487 5493003O0P1GJ0O8CI80 83955688.00000000 Deutsche Bank Securities, Inc. 8-17822 000002525 9J6MBOOO7BECTDTUZW19 41970227.00000000 Citadel Securities LLC 8-53574 000116797 12UUJYTN7D3SW8KCSG25 43622747.00000000 Morgan Stanley & Co., Inc. 8-15869 000008209 9R7GPTSO7KV3UQJZQ078 71722691.00000000 Barclays Capital, Inc. 8-41342 000019714 AC28XWWI3WIBK2824319 55944055.00000000 918318684.00000000 N 2066524351.05000000 Uncommitted 100000000.00000000 N Committed 1500000000.00000000 N N N N false false true false false false INTERNAL CONTROL RPT 2 JPM_Inst_Trust.htm FOR VALIDATION PURPOSES ONLY - [739794.ICRPT]

Report of Independent Registered Public Accounting Firm

To the Board of Trustees of JPMorgan Institutional Trust and Shareholders of the funds listed in Appendix A

In planning and performing our audit of the financial statements of the funds listed in Appendix A (constituting JPMorgan Institutional Trust, hereafter collectively referred to as the “Funds”) as of and for the year ended February 28, 2019, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), we considered the Funds’ internal control over financial reporting, including controls over safeguarding securities, as a basis for designing our auditing procedures for the purpose of expressing our opinion on the financial statements and to comply with the requirements of Form N-CEN, but not for the purpose of expressing an opinion on the effectiveness of the Funds’ internal control over financial reporting. Accordingly, we do not express an opinion on the effectiveness of the Funds’ internal control over financial reporting.

The management of the Funds is responsible for establishing and maintaining effective internal control over financial reporting. In fulfilling this responsibility, estimates and judgments by management are required to assess the expected benefits and related costs of controls. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of a company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

A deficiency in internal control over financial reporting exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.

Our consideration of the Funds’ internal control over financial reporting was for the limited purpose described in the first paragraph and would not necessarily disclose all deficiencies in internal control over financial reporting that might be material weaknesses under standards established by the PCAOB. However, we noted no deficiencies in the Funds internal control over financial reporting and their operations, including controls over safeguarding securities, that we consider to be material weaknesses as defined above as of February 28, 2019.

This report is intended solely for the information and use of the Board of Trustees of JPMorgan Institutional Trust and the Securities and Exchange Commission and is not intended to be and should not be used by anyone other than these specified parties.

 

/s/ PricewaterhouseCoopers LLP
New York, New York
April 26, 2019

 

2

Appendix A

JPMorgan Core Bond Trust

JPMorgan Intermediate Bond Trust

 

3